JP2004528286A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004528286A5 JP2004528286A5 JP2002558379A JP2002558379A JP2004528286A5 JP 2004528286 A5 JP2004528286 A5 JP 2004528286A5 JP 2002558379 A JP2002558379 A JP 2002558379A JP 2002558379 A JP2002558379 A JP 2002558379A JP 2004528286 A5 JP2004528286 A5 JP 2004528286A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- receptor
- functional
- receptors
- atp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000010099 disease Diseases 0.000 claims description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 25
- 210000001519 tissue Anatomy 0.000 claims description 21
- 206010025323 Lymphomas Diseases 0.000 claims description 14
- 210000002919 epithelial cell Anatomy 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 210000000481 breast Anatomy 0.000 claims description 10
- 201000009030 Carcinoma Diseases 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 230000001613 neoplastic effect Effects 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 210000002307 prostate Anatomy 0.000 claims description 8
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 6
- 230000002496 gastric effect Effects 0.000 claims description 5
- 201000005787 hematologic cancer Diseases 0.000 claims description 5
- 210000004072 lung Anatomy 0.000 claims description 5
- 210000003491 skin Anatomy 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 210000001072 colon Anatomy 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 210000003932 urinary bladder Anatomy 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 210000003238 esophagus Anatomy 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 206010046766 uterine cancer Diseases 0.000 claims description 2
- 210000004291 uterus Anatomy 0.000 claims description 2
- 206010046885 vaginal cancer Diseases 0.000 claims description 2
- 208000013139 vaginal neoplasm Diseases 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- IHUKVJKKTBLTEE-QMMMGPOBSA-N (2s)-2-acetamido-5-[[amino-(methylcarbamoylamino)methylidene]amino]-n-methylpentanamide Chemical compound CNC(=O)NC(N)=NCCC[C@H](NC(C)=O)C(=O)NC IHUKVJKKTBLTEE-QMMMGPOBSA-N 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 210000001215 vagina Anatomy 0.000 claims 1
- 102000005962 receptors Human genes 0.000 description 125
- 108020003175 receptors Proteins 0.000 description 125
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 49
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 48
- 210000004027 cell Anatomy 0.000 description 48
- 206010028980 Neoplasm Diseases 0.000 description 25
- 239000000523 sample Substances 0.000 description 24
- 201000011510 cancer Diseases 0.000 description 17
- 208000002551 irritable bowel syndrome Diseases 0.000 description 14
- 230000008859 change Effects 0.000 description 11
- 239000008194 pharmaceutical composition Substances 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 239000000203 mixture Substances 0.000 description 10
- 239000000556 agonist Substances 0.000 description 8
- 230000006907 apoptotic process Effects 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 7
- 210000003719 b-lymphocyte Anatomy 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 210000004408 hybridoma Anatomy 0.000 description 6
- 239000011148 porous material Substances 0.000 description 6
- 108091006146 Channels Proteins 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 238000003782 apoptosis assay Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 210000000981 epithelium Anatomy 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 210000000265 leukocyte Anatomy 0.000 description 5
- 230000005522 programmed cell death Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 108091006112 ATPases Proteins 0.000 description 4
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 4
- 230000001594 aberrant effect Effects 0.000 description 4
- 230000005669 field effect Effects 0.000 description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- 102100029722 Ectonucleoside triphosphate diphosphohydrolase 1 Human genes 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 101001012447 Homo sapiens Ectonucleoside triphosphate diphosphohydrolase 1 Proteins 0.000 description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 101150035600 atpD gene Proteins 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- LYLMANSTAHZWBY-UHFFFAOYSA-N 1-[6-(1-hydroxy-2,5-dioxopyrrolidin-3-yl)-6-oxohexyl]pyrrole-2,5-dione Chemical compound O=C1N(O)C(=O)CC1C(=O)CCCCCN1C(=O)C=CC1=O LYLMANSTAHZWBY-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 239000004971 Cross linker Substances 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 2
- 102000002294 Purinergic P2X Receptors Human genes 0.000 description 2
- 108010000836 Purinergic P2X Receptors Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 210000005205 gut mucosa Anatomy 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 102100022464 5'-nucleotidase Human genes 0.000 description 1
- 229940121819 ATPase inhibitor Drugs 0.000 description 1
- 108010080422 CD39 antigen Proteins 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000006994 Precancerous Conditions Diseases 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 102000000033 Purinergic Receptors Human genes 0.000 description 1
- 108010080192 Purinergic Receptors Proteins 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 102000019215 Supervillin Human genes 0.000 description 1
- 108050006606 Supervillin Proteins 0.000 description 1
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000362 adenosine triphosphatase inhibitor Substances 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 208000003373 basosquamous carcinoma Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 238000012303 cytoplasmic staining Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 108010047482 ectoATPase Proteins 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 238000012309 immunohistochemistry technique Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 230000004526 pharmaceutical effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPR2579A AUPR257901A0 (en) | 2001-01-17 | 2001-01-17 | Diagnosis and treatment of malignant lymphoma |
| AUPR5891A AUPR589101A0 (en) | 2001-06-22 | 2001-06-22 | Diagnosis of cell cancers using an antibody to non-functionalP2X, receptors |
| AUPR5890A AUPR589001A0 (en) | 2001-06-22 | 2001-06-22 | An antibody cancer therapeutic |
| AUPR7431A AUPR743101A0 (en) | 2001-09-03 | 2001-09-03 | A cancer therapeutic |
| AUPR7430A AUPR743001A0 (en) | 2001-09-03 | 2001-09-03 | Diagnosis and treatment of irritable bowel syndrome |
| PCT/AU2002/000061 WO2002057306A1 (en) | 2001-01-17 | 2002-01-17 | Antibodies to non-functional p2x7 receptor diagnosis and treatment of cancers and other conditions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009112881A Division JP4457169B2 (ja) | 2001-01-17 | 2009-05-07 | 非機能性ｐ２ｘ７レセプター抗体、癌及びその他の容態の診断及び処理 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004528286A JP2004528286A (ja) | 2004-09-16 |
| JP2004528286A5 true JP2004528286A5 (https=) | 2008-12-25 |
| JP4384852B2 JP4384852B2 (ja) | 2009-12-16 |
Family
ID=27507500
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002558379A Expired - Fee Related JP4384852B2 (ja) | 2001-01-17 | 2002-01-17 | 非機能性ｐ２ｘ７レセプター抗体、癌及びその他の容態の診断及び処置 |
| JP2009112881A Expired - Lifetime JP4457169B2 (ja) | 2001-01-17 | 2009-05-07 | 非機能性ｐ２ｘ７レセプター抗体、癌及びその他の容態の診断及び処理 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009112881A Expired - Lifetime JP4457169B2 (ja) | 2001-01-17 | 2009-05-07 | 非機能性ｐ２ｘ７レセプター抗体、癌及びその他の容態の診断及び処理 |
Country Status (14)
| Country | Link |
|---|---|
| US (10) | US7326415B2 (https=) |
| EP (2) | EP1360203B1 (https=) |
| JP (2) | JP4384852B2 (https=) |
| CN (2) | CN100497385C (https=) |
| AT (2) | ATE548383T1 (https=) |
| AU (1) | AU2003235005B2 (https=) |
| CA (1) | CA2434490C (https=) |
| DE (1) | DE60230482D1 (https=) |
| DK (2) | DK1961767T3 (https=) |
| ES (2) | ES2383712T3 (https=) |
| MY (1) | MY158262A (https=) |
| PT (1) | PT1360203E (https=) |
| TW (1) | TWI319011B (https=) |
| WO (1) | WO2002057306A1 (https=) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPP991199A0 (en) * | 1999-04-21 | 1999-05-13 | University Of Sydney, The | Methods for diagnosing pre-cancerous and cancerous conditions |
| AUPR201500A0 (en) * | 2000-12-11 | 2001-01-11 | Biosceptre Pty Ltd | Methods for identifying pre-neoplastic and neoplastic states in mammals |
| EP1360203B1 (en) | 2001-01-17 | 2008-12-24 | Intreat Pty Limited | Antibodies to non-functional p 2 x 7 receptor diagnosis and treatment of cancers and other conditions |
| NZ565994A (en) * | 2001-09-03 | 2010-02-26 | Intreat Pty Ltd | Antibodies to non-functional P2X7 receptor, diagnosis and treatment of cancers and other conditions |
| CN100515494C (zh) * | 2001-12-12 | 2009-07-22 | 启龙有限公司 | 抗沙眼衣原体的免疫 |
| GB0229139D0 (en) * | 2002-12-13 | 2003-01-15 | Glaxo Group Ltd | Gene polymorphisms |
| WO2007146061A2 (en) * | 2006-06-09 | 2007-12-21 | University Hospitals Of Cleveland | Cell collection and disease screening |
| WO2008043146A1 (en) * | 2006-10-10 | 2008-04-17 | Biosceptre International Limited | Antibodies against non functional p2x7 receptor |
| JP2010505426A (ja) | 2006-10-10 | 2010-02-25 | バイオスセプター インターナショナル リミテッド | 非機能性ｐ２ｘ７受容体に対する抗体を産生するハイブリドーマ |
| AU2008299593B2 (en) | 2007-09-14 | 2013-04-18 | Biosceptre International Limited | Novel P2X7 epitopes |
| AU2013238152B2 (en) * | 2007-09-14 | 2015-09-24 | Biosceptre International Limited | Purinergic (P2X) receptors in extra-cellular body fluid |
| AU2008299594B2 (en) * | 2007-09-14 | 2013-10-03 | Biosceptre International Limited | Purinergic (P2X) receptors in extra-cellular body fluid |
| BRPI0915367B8 (pt) | 2008-07-04 | 2021-05-25 | Biosceptre International Ltd | peptídeo anti-p2x7 |
| EP3470425A3 (en) * | 2008-12-19 | 2019-07-17 | Ablynx N.V. | Immunoglobulins against cell-associatd antigens such as p2x7 |
| ES2904911T3 (es) * | 2009-08-20 | 2022-04-06 | Biosceptre Aust Pty Ltd | Anticuerpos anti-receptor P2X7 y fragmentos de los mismos |
| WO2011056561A1 (en) * | 2009-10-27 | 2011-05-12 | Beth Israel Deaconess Medical Center | Methods and compositions for the generation and use of conformation-specific antibodies |
| JP5992831B2 (ja) | 2009-12-24 | 2016-09-14 | バイオセプター・（オーストラリア）・ピーティーワイ・リミテッド | 非機能性オリゴマーｐ２ｘ７受容体に対する抗体 |
| CN106310245A (zh) * | 2010-09-10 | 2017-01-11 | 生物权威(澳大利亚)有限责任公司 | 陪伴动物治疗 |
| WO2012149334A2 (en) * | 2011-04-27 | 2012-11-01 | Beth Israel Deaconess Medical Center, Inc. | Methods and compositions for the generation and use of conformation-specific antibodies |
| US9566318B2 (en) * | 2011-07-01 | 2017-02-14 | Biosceptre (Aust) Pty Ltd | Combination therapy |
| EP3347474B1 (en) | 2015-09-11 | 2020-11-04 | Biosceptre (UK) Limited | Chimeric antigen receptors and uses thereof |
| CN109862883A (zh) * | 2016-10-21 | 2019-06-07 | 生物权威（英国）有限公司 | 细胞毒性颗粒 |
| BR122023024273A2 (pt) | 2018-02-27 | 2024-02-20 | Incyte Corporation | Compostos imidazopirimidinas e triazolopirimidinas, seus usos, método para inibir uma atividade de um receptor de adenosina e composição farmacêutica dos mesmos |
| WO2019222677A1 (en) | 2018-05-18 | 2019-11-21 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
| GEP20237548B (en) | 2018-07-05 | 2023-10-10 | Incyte Corp | Fused pyrazine derivatives as a2a /a2b inhibitors |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| CN110054691B (zh) * | 2019-05-09 | 2021-09-07 | 潍坊医学院 | 一种抗人p2rx7单克隆抗体的杂交瘤细胞系 |
| WO2021019222A1 (en) * | 2019-07-26 | 2021-02-04 | Biosceptre (Uk) Limited | P2x7 receptor targeted therapy |
| CA3166536A1 (en) | 2020-01-03 | 2021-07-08 | Incyte Corporation | Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy |
| WO2021138467A1 (en) | 2020-01-03 | 2021-07-08 | Incyte Corporation | Anti-cd73 antibodies and uses thereof |
| MX2023007850A (es) | 2020-12-29 | 2023-09-11 | Incyte Corp | Terapia combinada que comprende inhibidores de adora2a/adora2b (a2a/a2b), inhibidores de muerte programada/ligando 1 de muerte programada (pd-1/pd-l1) y anticuerpos de cumulo de diferenciacion 73 (anti-cd73). |
| JP2024513485A (ja) * | 2021-04-08 | 2024-03-25 | バイオセプター （オースト） プロプライエタリー・リミテッド | 免疫細胞活性を制御する方法 |
| CA3267581A1 (en) * | 2022-09-14 | 2024-03-21 | Biosceptre (Aust) Pty Ltd | IN VIVO DETECTION OF IMMUNE CELLS |
| US20260085104A1 (en) * | 2022-09-14 | 2026-03-26 | Biosceptre (Aust) Pty Ltd | Methods of detecting immune cells |
| EP4587465A1 (en) * | 2022-09-14 | 2025-07-23 | Biosceptre (Aust) Pty Ltd | Enrichment of engineered immune cells |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1141314A (en) * | 1914-12-19 | 1915-06-01 | Eugene W Caldwell | Photographic developing apparatus. |
| US2191508A (en) * | 1939-02-06 | 1940-02-27 | Stuart Robert | Photographic film carrier and development receptacle |
| US3010460A (en) * | 1958-07-03 | 1961-11-28 | Geo B Hart Inc | Apparatus for wetting absorbent bodies for moistening and supporting plant parts |
| US3077155A (en) * | 1960-08-08 | 1963-02-12 | Pako Corp | Device for treating photographic sheet material |
| US3121438A (en) * | 1961-01-16 | 1964-02-18 | Union Carbide Corp | Open head container and cover therefor |
| US3952756A (en) * | 1974-06-14 | 1976-04-27 | Purex Corporation | Semi automatic parts cleaning machine |
| US4302273A (en) * | 1980-06-04 | 1981-11-24 | Rca Corporation | Etching tank in which the solution circulates by convection |
| US4305413A (en) * | 1980-07-25 | 1981-12-15 | Ecology, Inc. | Cleaning apparatus |
| US4550579A (en) * | 1984-04-13 | 1985-11-05 | Frank Clifford G | Apparatus for the dyeing of shaped articles |
| US5104727A (en) * | 1989-06-16 | 1992-04-14 | W. L. Gore & Associates, Inc. | Air bag laminates |
| IE920765A1 (en) | 1991-03-12 | 1992-09-23 | Scripps Research Inst | Cell surface receptors homologous to coagulation factors v¹and viii |
| JPH0756015A (ja) * | 1993-08-18 | 1995-03-03 | Sony Corp | カラーフィルタの製造方法 |
| WO1995033048A2 (en) | 1994-05-27 | 1995-12-07 | Glaxo Group Limited | P2x receptors (purinoceptor family) |
| US5660640A (en) * | 1995-06-16 | 1997-08-26 | Joray Corporation | Method of removing sputter deposition from components of vacuum deposition equipment |
| US5981218A (en) | 1995-08-09 | 1999-11-09 | Bristol-Myers Squibb Company | Isolated nucleic acid molecules useful as leukemia markers and in breast cancer prognosis and encoded polypeptides |
| JP2001521372A (ja) | 1996-04-30 | 2001-11-06 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | ヒトＰ２ｘ４レセプタースプライス−変異体 |
| US6303338B1 (en) | 1996-08-16 | 2001-10-16 | Human Genome Sciences, Inc. | Pancreas-derived plasminogen activator inhibitor |
| US6306393B1 (en) * | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
| JP3885177B2 (ja) | 1997-03-26 | 2007-02-21 | 大塚製薬株式会社 | ヒト遺伝子 |
| US6133434A (en) | 1997-04-28 | 2000-10-17 | Glaxo Group Limited | Purinergic receptor |
| US5851307A (en) * | 1997-04-28 | 1998-12-22 | Advanced Micro Devices, Inc. | Method for in-situ cleaning of polysilicon-coated quartz furnaces |
| US5849091A (en) * | 1997-06-02 | 1998-12-15 | Micron Technology, Inc. | Megasonic cleaning methods and apparatus |
| US5906216A (en) * | 1997-10-10 | 1999-05-25 | Barlet; Bruce N. | Denture cleaning device |
| AU757698C (en) * | 1998-06-01 | 2004-04-08 | Agensys, Inc. | Novel serpentine transmembrane antigens expressed in human cancers and uses thereof |
| DE19829473C2 (de) | 1998-07-01 | 2000-08-10 | Magnus Von Knebel Doeberitz Ch | Verfahren zur frühen Diagnose von Carcinomen |
| US6055694A (en) * | 1998-11-30 | 2000-05-02 | Tsk America, Inc. | Wafer scrubbing machine |
| EP1157038A4 (en) | 1999-02-26 | 2005-01-19 | Smithkline Beecham Corp | CLONING OF A P2Y-LIKE 7TM RECEPTOR (AXOR17) |
| AUPP991199A0 (en) | 1999-04-21 | 1999-05-13 | University Of Sydney, The | Methods for diagnosing pre-cancerous and cancerous conditions |
| NL1012452C2 (nl) | 1999-06-28 | 2001-01-02 | Univ Delft Tech | Werkwijze voor de bereiding van eiwit-agglomeraten, eiwit-agglomeraten, een levensmiddel en een farmaceutisch preparaat die deze bevatten alsmede een inrichting voor het bereiden van eiwit-agglomeraten. |
| WO2001030964A2 (en) | 1999-10-22 | 2001-05-03 | Lifespan Biosciences, Inc. | Anti-cancer nucleic acid and protein targets |
| AUPR201500A0 (en) | 2000-12-11 | 2001-01-11 | Biosceptre Pty Ltd | Methods for identifying pre-neoplastic and neoplastic states in mammals |
| EP1360203B1 (en) | 2001-01-17 | 2008-12-24 | Intreat Pty Limited | Antibodies to non-functional p 2 x 7 receptor diagnosis and treatment of cancers and other conditions |
| NZ565994A (en) | 2001-09-03 | 2010-02-26 | Intreat Pty Ltd | Antibodies to non-functional P2X7 receptor, diagnosis and treatment of cancers and other conditions |
| EP1469072B1 (en) | 2003-04-17 | 2007-08-29 | Affectis Pharmaceuticals AG | Means and methods for diagnosing and treating affective disorders |
| CA2607541A1 (en) | 2005-05-05 | 2006-12-28 | Medicure International Inc. | Inhibition of atp-mediated, p2x7 dependent pathways by pyridoxal-5-phosphaste and vitamin b6 related compounds |
| US7767789B2 (en) * | 2005-06-02 | 2010-08-03 | University Hopitals of Cleveland | Truncated proteins as cancer markers |
| WO2007027957A2 (en) | 2005-08-31 | 2007-03-08 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in leukemia signaling pathways |
| JP2010505426A (ja) | 2006-10-10 | 2010-02-25 | バイオスセプター インターナショナル リミテッド | 非機能性ｐ２ｘ７受容体に対する抗体を産生するハイブリドーマ |
| WO2008043146A1 (en) | 2006-10-10 | 2008-04-17 | Biosceptre International Limited | Antibodies against non functional p2x7 receptor |
| AU2008299593B2 (en) | 2007-09-14 | 2013-04-18 | Biosceptre International Limited | Novel P2X7 epitopes |
| AU2008299594B2 (en) | 2007-09-14 | 2013-10-03 | Biosceptre International Limited | Purinergic (P2X) receptors in extra-cellular body fluid |
| BRPI0915367B8 (pt) | 2008-07-04 | 2021-05-25 | Biosceptre International Ltd | peptídeo anti-p2x7 |
| ES2904911T3 (es) | 2009-08-20 | 2022-04-06 | Biosceptre Aust Pty Ltd | Anticuerpos anti-receptor P2X7 y fragmentos de los mismos |
| JP5992831B2 (ja) | 2009-12-24 | 2016-09-14 | バイオセプター・（オーストラリア）・ピーティーワイ・リミテッド | 非機能性オリゴマーｐ２ｘ７受容体に対する抗体 |
| WO2011131472A1 (en) | 2010-04-22 | 2011-10-27 | Institut Gustave Roussy | Compounds and uses thereof to induce an immunogenic cancer cell death in a subject |
| CN106310245A (zh) | 2010-09-10 | 2017-01-11 | 生物权威(澳大利亚)有限责任公司 | 陪伴动物治疗 |
| US9566318B2 (en) | 2011-07-01 | 2017-02-14 | Biosceptre (Aust) Pty Ltd | Combination therapy |
-
2002
- 2002-01-17 EP EP02715313A patent/EP1360203B1/en not_active Expired - Lifetime
- 2002-01-17 TW TW091100845A patent/TWI319011B/zh not_active IP Right Cessation
- 2002-01-17 AT AT08156593T patent/ATE548383T1/de active
- 2002-01-17 PT PT02715313T patent/PT1360203E/pt unknown
- 2002-01-17 ES ES08156593T patent/ES2383712T3/es not_active Expired - Lifetime
- 2002-01-17 CA CA2434490A patent/CA2434490C/en not_active Expired - Lifetime
- 2002-01-17 AT AT02715313T patent/ATE418565T1/de active
- 2002-01-17 JP JP2002558379A patent/JP4384852B2/ja not_active Expired - Fee Related
- 2002-01-17 DE DE60230482T patent/DE60230482D1/de not_active Expired - Lifetime
- 2002-01-17 CN CNB028050789A patent/CN100497385C/zh not_active Expired - Lifetime
- 2002-01-17 EP EP08156593A patent/EP1961767B1/en not_active Expired - Lifetime
- 2002-01-17 WO PCT/AU2002/000061 patent/WO2002057306A1/en not_active Ceased
- 2002-01-17 DK DK08156593.9T patent/DK1961767T3/da active
- 2002-01-17 DK DK02715313T patent/DK1360203T3/da active
- 2002-01-17 ES ES02715313T patent/ES2320421T3/es not_active Expired - Lifetime
- 2002-01-17 CN CN2009101328012A patent/CN101555283B/zh not_active Expired - Lifetime
- 2002-01-17 MY MYPI20020182A patent/MY158262A/en unknown
-
2003
- 2003-07-17 US US10/622,313 patent/US7326415B2/en not_active Expired - Lifetime
- 2003-08-14 AU AU2003235005A patent/AU2003235005B2/en not_active Expired
-
2008
- 2008-01-02 US US11/968,607 patent/US7531171B2/en not_active Expired - Lifetime
-
2009
- 2009-04-03 US US12/417,989 patent/US7888473B2/en not_active Expired - Fee Related
- 2009-05-07 JP JP2009112881A patent/JP4457169B2/ja not_active Expired - Lifetime
-
2010
- 2010-12-21 US US12/975,341 patent/US8080635B2/en not_active Expired - Fee Related
-
2011
- 2011-11-16 US US13/298,222 patent/US8399617B2/en not_active Expired - Fee Related
-
2013
- 2013-02-13 US US13/766,630 patent/US8709425B2/en not_active Expired - Fee Related
-
2014
- 2014-03-18 US US14/218,935 patent/US20140323693A1/en not_active Abandoned
-
2015
- 2015-05-29 US US14/726,391 patent/US9663584B2/en not_active Expired - Fee Related
-
2017
- 2017-04-26 US US15/498,301 patent/US10450380B2/en not_active Expired - Fee Related
-
2019
- 2019-09-11 US US16/568,072 patent/US20200071419A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4457169B2 (ja) | 非機能性ｐ２ｘ７レセプター抗体、癌及びその他の容態の診断及び処理 | |
| JP2004528286A5 (https=) | ||
| AU2002322192B2 (en) | Antibodies to non-functional P2X7receptor, diagnosis and treatment of cancers and other conditions | |
| AU2002322192A1 (en) | Antibodies to non-functional P2X7receptor, diagnosis and treatment of cancers and other conditions | |
| HK1138013B (en) | Antibodies to non-functional p2x7 receptor diagnosis and treatment of cancers and other conditions | |
| HK1070903B (en) | Antibodies to non-functional p2x7 receptor diagnosis and treatment of cancers and other conditions |